HomeInvestors HealthOrganon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma By BOMAR ENT. September 6, 2024 FacebookTwitterPinterestWhatsApp Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Source link Previous articleWhy Zscaler Stock Was Sliding This WeekNext articleIs Nvidia a Safe Stock to Own During a Recession? latest articles explore more Do You Really Need All Those Phone Plan Perks? How to Find a Simpler, Cheaper Option Investing in Small-Caps: The ultimate Guide Are $100K Rental Properties Ever Worth It? The Ages of the Investor: A Critical Look at Life-cycle Investing (Investing for Adults Book 1) The Intelligent Investor Rev Ed. S&P 500 Hits New High Before Big Tech Earnings, Fed: Stock Market Today LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment.